|
|
 |
|
Viewing report
|
|
|
|
Biogenerics: Drivers and Resistors of Market Development
Datamonitor, April 2004
With several blockbuster biological products approaching patent expiry, the biogenerics segment represents an attractive opportunity for companies looking to escape intensifying competition in the commodity generics sector. The generics industry is pushing for establishment of an approval pathway for generic biologics, but even once this is in place, barriers to market entry will be high.
Scope of this report:
- Evaluation of developments in the regulatory environment for biogenerics in the US and EU
- Analysis of market entry strategies of likely key biogenerics players
- Assessment of the market potential of biogenerics, and the barriers to companies wishing to exploit this.
Report Highlights
While the US represents the major market for regular generics, in the case of biogenerics, Europe is leading the development of the Western market, with the issue having been addressed as part of a restructuring of pharmaceutical legislation, making Europe the first market to establish a legal framework for authorization of biogenerics.
Despite the high potential, relatively few companies are expected to enter Western biogenerics markets due to high barriers to entry. Companies may try to overcome these barriers by entering the superbiogenerics market, where higher returns are achievable.
Players in the biogenerics market fall into two key categories: biotech start-ups such as Cangene, Microbix and GeneMedix, and established generics companies looking to expand their existing portfolios such as Stada, Teva, and Sandoz.
“...If you are trying to play the game we have all tried before -to all work from the same list for 90% of those products, the Indians will be able to do it cheaper and quicker. Companies will need to move to value added, barrier to entry products to survive...”
Generics Company Executive
Reasons to Purchase
1. Evaluate the strategies of key biogenerics contenders, and assess their threat to your business
2. Understand the key regulatory issues surrounding approval of biogenerics
3. Assess the barriers to entry in the biogenerics sector, as well as the market potential
“...You have to look at value added products, even in generics…
where there is the opportunity for value added products, derived from the
greater complexity in development and approval, the margins are greater...”
Generics Company Executive
Customers who bought this item also bought
Biogenerics 2005: A New Level Of Complexity
The Biogenerics Market Outlook: An Analysis of Market Dynamics, Growth Drivers and Leading Players
Pharmaceutical R&D Outsourcing Strategies: An Analysis of Market Drivers and Resistors to 2010
Pharmaceutical Pricing Strategies: Price optimization, reimbursement and regulation in Europe, US and Japan
Biogenerics: Challenges and Promise
The Pharmaceutical Market Outlook to 2015: Implementing innovative, long-term strategies for sustainable future growth
Future Drivers: Sales Forecast to 2005
Pharmaceutical And Biotech Growth Strategies: Future Drivers And Opportunities
|
|
|
|
